Local Biotech Firm Develops Drug For Respiratory Distress In COVID-19 Patients

Local Biotech Firm Develops Drug For Respiratory Distress In COVID-19 Patients

Pittsburgh-based biotech company CytoAgents is launching into phase one of clinical trials this month on a drug designed to treat people with COVID-19 who develop serious respiratory distress when their immune system overreacts to the virus. Read more >>

Share this post